Angiodynamics (ANGO) Receivables (2011 - 2026)

Angiodynamics (ANGO) has reported Receivables for 16 consecutive years, with $48.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 12.67% year-over-year to $48.3 million; the trailing twelve-month figure through May 2026 stood at $48.3 million (up 12.67% YoY), and the FY2026 full-year result was $48.3 million, up 12.67% from the prior year.
• Receivables improved to $48.3 million in Q2 2026 per ANGO's latest filing, from $45.6 million in the prior quarter.
• Across five years, Receivables topped out at $53.6 million in Q3 2022 and bottomed at $39.6 million in Q3 2024.
• Historically, Receivables has averaged $47.2 million across 5 years, with a median of $46.9 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Receivables jumped 51.3% in 2022, then retreated 20.48% in 2024.
• Over 5 years, Receivables stood at $52.9 million in 2022, then fell by 2.36% to $51.6 million in 2023, then decreased by 16.37% to $43.2 million in 2024, then grew by 2.96% to $44.4 million in 2025, then advanced by 8.76% to $48.3 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $48.3 million, $45.6 million, and $44.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.